Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
Public ClinicalTrials.gov record NCT03257761. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients With Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase Ib trial studies the side effects and best dose of guadecitabine and how well it works when given together with durvalumab in treating patients with liver, pancreatic, bile duct, or gallbladder cancer that has spread to other places in the body. Guadecitabine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as durvalumab, may block tumor growth in different ways by targeting certain cells. Giving guadecitabine and durvalumab may work better in treating patients with liver, pancreatic, bile duct, or gallbladder cancer.
Study identification
- NCT ID
- NCT03257761
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 55 participants
Conditions and interventions
Conditions
- Extrahepatic Bile Duct Adenocarcinoma, Biliary Type
- Gallbladder Adenocarcinoma, Biliary Type
- Metastatic Pancreatic Adenocarcinoma
- Recurrent Cholangiocarcinoma
- Recurrent Gallbladder Carcinoma
- Recurrent Hepatocellular Carcinoma
- Recurrent Intrahepatic Cholangiocarcinoma
- Recurrent Pancreatic Carcinoma
- Stage III Gallbladder Cancer AJCC V7
- Stage III Hepatocellular Carcinoma AJCC v7
- Stage III Intrahepatic Cholangiocarcinoma AJCC v7
- Stage III Pancreatic Cancer AJCC v6 and v7
- Stage IIIA Gallbladder Cancer AJCC v7
- Stage IIIA Hepatocellular Carcinoma AJCC v7
- Stage IIIB Gallbladder Cancer AJCC v7
- Stage IIIB Hepatocellular Carcinoma AJCC v7
- Stage IIIC Hepatocellular Carcinoma AJCC v7
- Stage IV Gallbladder Cancer AJCC v7
- Stage IV Hepatocellular Carcinoma AJCC v7
- Stage IV Pancreatic Cancer AJCC v6 and v7
- Stage IVA Gallbladder Cancer AJCC v7
- Stage IVA Hepatocellular Carcinoma AJCC v7
- Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7
- Stage IVB Gallbladder Cancer AJCC v7
- Stage IVB Hepatocellular Carcinoma AJCC v7
- Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7
- Unresectable Gallbladder Carcinoma
- Unresectable Pancreatic Carcinoma
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 6, 2018
- Primary completion
- Sep 26, 2021
- Completion
- Dec 30, 2026
- Last update posted
- May 31, 2026
2018 – 2026
United States locations
- U.S. sites
- 3
- U.S. states
- 2
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC / Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Hoag Memorial Hospital Presbyterian | Newport Beach | California | 92663 | — |
| Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore | Maryland | 21287 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03257761, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 31, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03257761 live on ClinicalTrials.gov.